We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combinatorial drug therapy for cancer in the post-genomic era.
- Authors
Al-Lazikani, Bissan; Banerji, Udai; Workman, Paul
- Abstract
Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.
- Subjects
COMBINATION drug therapy; CANCER chemotherapy; NUCLEOTIDE sequence; GENETIC mutation; CANCER cells; INDIVIDUALIZED medicine; DRUG resistance in cancer cells
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 7, p679
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt.2284